Figure 8.
Potentiation of antitumour activity of polymer-bound mebendazole conjugate through IL-2 immunocomplexes in vivo. B6 mice (n = 8) were s.c. inoculated with 105 EL-4 cells on day 0, then i.p. injected with 3 doses (100 mg mebendazole/kg per one dose) of HPMA copolymer-bound mebendazole conjugate (P-MBZ-A (3 × 100)) on days 8, 10, and 12, or with the latter plus complexes of IL-2 and anti-IL-2 mAb S4B6 mAb (2.5 µg IL-2 per one dose) on days 14, 16, and 18 (P-MBZ-A (3 × 100) + IL-2co). Untreated mice were used as controls. Tumour growth (A), body weight (B), and survival (C) were monitored, and each experimental point (A,B) is the average of the experimental group ± SD.